WallStSmart

BP PLC ADR (BP)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BP PLC ADR generates 537% more annual revenue ($187.64B vs $29.44B). GILD leads profitability with a 28.9% profit margin vs 0.0%. BP appears more attractively valued with a PEG of 0.18. GILD earns a higher WallStSmart Score of 72/100 (B).

BP

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 4.5Value: 4.7Quality: 5.0

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 10.0Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPSignificantly Overvalued (-4001.1%)

Margin of Safety

-4001.1%

Fair Value

$0.94

Current Price

$44.79

$43.85 premium

UndervaluedFair: $0.94Overvalued
GILDUndervalued (+53.9%)

Margin of Safety

+53.9%

Fair Value

$299.95

Current Price

$138.26

$161.69 discount

UndervaluedFair: $299.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP3 strengths · Avg: 9.0/10
PEG RatioValuation
0.1810/10

Growing faster than its price suggests

Market CapQuality
$114.71B9/10

Large-cap with strong market position

Free Cash FlowQuality
$4.14B8/10

Generating 4.1B in free cash flow

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$171.45B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

BP4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Return on EquityProfitability
1.7%3/10

ROE of 1.7% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, Market Cap, Free Cash Flow. PEG of 0.18 suggests the stock is reasonably priced for its growth.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : BP

The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2239.0x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Key Dynamics to Monitor

GILD carries more volatility with a beta of 0.37 — expect wider price swings.

GILD is growing revenue faster at 4.7% — sustainability is the question.

BP generates stronger free cash flow (4.1B), providing more financial flexibility.

Monitor OIL & GAS INTEGRATED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GILD scores higher overall (72/100 vs 54/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?